1. Temporal profiles of more than 4000 phosphopeptides after stimulating human platelets (a) with ADP and (b) consecutively with ADP and Iloprost.
Introduction
In circulating platelets the equilibrium between activation and inhibition pathways is well-balanced to prevent uncontrolled platelet aggregation in the absence of vascular damage or injury. Upon vascular lesion, defined partly platelet-derived stimuli can shift this equilibrium toward activation within seconds. ADP, rapidly released by activated platelets 1 and also present in plasma in low amounts 1 derived from cellular ATP (erythrocytes, endothelial cells), enhances platelet activation by virtually any other stimulant to complete platelet aggregation and thrombus formation. 2 It binds specifically to the G-protein coupled receptors P2Y1 and P2Y12 3 stimulating intracellular phosphorylation-based pathways via the G-proteins Gqα and Giα, respectively. Whereas Gqα activates phospholipase Cβ (PLCβ) and calciumdependent Rac signaling 4 , Giα inhibits cAMP production leading to impaired protein kinase A (PKA) activity. Moreover, Giβγ also stimulates phosphoinositide 3-kinases and subsequent phosphorylation pathways required for integrin activation. 5 PLC isoforms hydrolyze the second messenger 1-phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 3 , which activate downstream signaling, mainly through protein kinase C (PKC/PRKC) and calcium sequestration from intracellular stores. Inhibitors of the ADP receptor P2Y12 (e.g. clopidogrel and prasugrel metabolites) are among the most successful anti-platelet drugs. 6, 7 They are considered the best available medication for preventing severe incidents during angiography, but also as secondary prophylaxis after cardiovascular events. However, these drugs show remarkable variability regarding efficacy, ranging from deficient metabolism of the prodrug, to incomplete receptor or signaling inhibition. [8] [9] [10] We reasoned that a more detailed molecular understanding of ADP-induced protein phosphorylation can help to identify critical hubs and sensitive components of the signaling networks governing aggregation, secretion and other responses, as well as novel molecular targets for anti-platelet treatment strategies. Quantitative phosphoproteomics has a great potential to elucidate cellular signaling cascades 11 even when applied to study primary tissues. 9, 12, 13 Here, we used quantitative mass spectrometry (MS) to study temporal phosphorylation patterns in human platelets (i) after stimulation with ADP, and, in order to mimic the antagonistic efficacy of endothelial-derived prostacyclin, (ii) after consecutive stimulation with ADP and Iloprost. We provide temporal profiles for 4,797 phosphorylated peptides, 608 out of For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From which (from 393 proteins) showed significant regulation. Among those, some participate in well-established activating functions such as degranulation and cytoskeletal re-organization, while others contribute to less well-understood pathways.
Methods

Platelet isolation and stimulation
Fresh blood was obtained from healthy volunteers who had not received any medication for two weeks, according to the declaration of Helsinki and approval by the ethics committee of the University of Würzburg (Study Numbers: 67/92 and 114/04).
Whole blood collection and platelet isolation were performed as described previously. 14 Platelet preparations were 99.999% pure, contamination with erythrocytes and leukocytes were lower than 1/10 4 platelets and 1/10 6 platelets. Each platelet preparation (biological triplicates) was split into four aliquots. For temporal ADP profiles aliquots were stimulated with 20 µM of ADP for 10, 30, 60 s, or remained unstimulated.
Additionally, to study changes reversed by Iloprost, platelet preparations (biological triplicates) were split as following: (i) unstimulated control; (ii) 20 µM ADP for 30 s; (iii) 20 µM ADP for 30 s followed by 2 nM Iloprost for 30 s; (iv) 20 µM ADP for 30 s followed by 2 nM Iloprost for 60 s. Owing to the lower sensitivity of methods other than LaSca the ADP concentration had to be increased for improved reproducibility. In all cases, signaling events were stopped by addition of lysis buffer (50 mM Tris, 1% SDS, 150 mM NaCl, 1 tablet PhosStop/10 mL, pH 7.8). Lysed samples were immediately shock frozen in liquid nitrogen and stored at -80 °C until further usage.
Quantitative (phospho)proteomics
Sample preparation, including proteolytic digestion 15, 16 and quality control 17 are detailed in the supplemental methods. Per donor and experiment, 100 µg of platelet digest were iTRAQ 4plex labeled, four time points pooled and phosphopeptides were enriched using TiO2 followed by fractionation using hydrophilic interaction liquid chromatography (HILIC) 18 
Aggregation measurements
Platelet shape change and aggregation were analyzed by quantification of angle dependent changes in scattered light intensity. 20 Briefly, platelet rich plasma (PRP) was diluted in 6 mL of modified HEPES buffer (pH 7.4, osmolarity 302 mOsm, containing 140 mM NaCl, 10 mM HEPES, 10 mM NaHCO3, 2 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM D-glucose) at a count of 1 x 10 7 platelets/mL. After 2 min of constant basal signal, platelets were stimulated by ADP and iloprost at indicated concentrations, and data were recorded for another 10 min. Platelet aggregation was monitored at a scatter angle of 1° to the laser beam, platelet shape change at an angle of 12°.
Western blot analysis
Washed platelets were stimulated with 20 µM of ADP (1 min), 2 nM Iloprost (1 min), or a combination thereof. SDS loading buffer was immediately added and proteins separated by SDS-PAGE. Separated proteins were transferred to a nitrocellulose membrane, blocked with 3% milk in TBS/0.1% Tween and incubated with primary antibodies against phospho-GRP2 Ser587 (CalDAG-GEFI; ImmunoGlobe, Himmelstadt, Germany), phospho-VASP Ser157 , phospho-VASP Ser239 (both Nanotools, Teningen, Germany), phospho-PKBS473, phospho-GSK3α Ser21 , phospho-GSK3β Ser9 , phospho-MARKS Ser159/Ser162 , phospho-p38 Thr180/Tyr182 , phospho-ERK Thr202/Tyr204 , phospho-MLC2 Thr18/Ser19 (all Cell Signaling, Frankfurt am Main, Germany) overnight at 4°C. For visualization, goat anti-rabbit or anti-mouse IgG conjugated with horseradish peroxidase were used as a secondary antibodies followed by ECL detection (Amersham, Pharmacia Biotech).
Rap1-GTP pull-down
Human platelets (3 x 10 8 /mL) were stimulated with ADP (10 µM, 1 min), Iloprost (2 nM, 1 min), or with Iloprost (2 nM, 1 min) after ADP stimulation. Following stimulation, platelets were lysed and Rap1-GTP was precipitated using GST-RalGDS-RBD coupled Sepharose beads. Before pull-down, 50 µL of the lysate was removed for analysis of the total proteins. The pull-down and total lysate were analyzed by Western blot with Rap1 specific antibody (Cell Signaling).
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Results
After ADP stimulation we quantified 3,952 phosphopeptides from 1,600 unique proteins, representing 1/3 of the platelet proteome. 21 Of these 436 phosphopeptides (302 proteins) were regulated upon stimulation with ADP (99% confidence in >2 biological replicates or >2-fold regulation in one). Remarkably, most regulated phosphorylation sites showed an early response already after For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
Different response of regulated biological pathways to ADP stimulation
To identify biological pathways involved in the dynamic phosphorylation changes we looked for GO-terms 22 enriched at specific time points using STRING. 23 In accordance with current knowledge, terms related to actin and the cytoskeleton were predominant. For most pathways regulation peaked after 10 s and decreased over time 
Substantial regulation of protein kinases and phosphatases
Among 302 ADP-regulated phosphoproteins were 33 kinases (>60 kinases found phosphorylated in total), mainly members of the STE (10), CAMK (8), AGC (5) and TK (4) families. This reflects the involvement of the MAPK cascade (STE), calciumbased regulation (CAMK), intracellular signaling mediated by cyclic nucleotides, phospholipids and calcium (AGC) and tyrosine phosphorylation (TK). Moreover, we found changes in six Tyr-phosphatases and three regulatory subunits. We grouped differential kinase and phosphatase phosphorylation sites as early (10 s ADP), medium (30 s) and late (60 s) responses (table 1) . Seven protein kinases were regulated on multiple sites; PKC delta (PRKCD) at four sites, three of those (Ser130, Thr218, Ser304) after 10 s and an additional one (Thr43) after 30 s of ADP stimulation.
Interestingly, PKC delta has recently been identified as a negative regulator of platelet aggregation and thrombus formation. 24 PAK2 and STK4/MST1 showed regulation after Analyzing up-regulated sites for the enriched occurrence of consensus motifs did not indicate particular protein kinases, probably owing to both a broad spectrum of involved kinases and inconclusive/overlapping kinase motifs. 
Family Uniprot Gene (alternative) Site Regulation
Ser130 
Modulation of ADP-induced phosphorylation by Iloprost
We wondered which phosphorylation changes induced by ADP can be reversed by prostacyclin. Initial functional experiments evaluating the ability of Iloprost to reverse ADP-induced platelet shape change and aggregation were performed using the recently established LaSca method, 20 which allows independent and simultaneous detection of shape change and aggregation (Supplemental fig. 1 ). This indicated that shape change peaked at 90 nM ADP, which was completely inhibited by 1 nM Iloprost (SF 1A). Nonlinear regression analysis revealed a Ki value of 0.035 ± 0.005 nM (SF 1C). Maximal platelet aggregation was achieved with 800 nM ADP, again completely inhibited by 1 nM Iloprost (SF 1D). The Ki value for inhibition by Iloprost was 0.053 ± 0.008 nM and calculated as described. 20 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From regulated phosphorylation sites consistently quantified in both datasets, i.e. the sole ADP time series and the ADP+Iloprost time series (368 proteins), and classified them into three categories: (i) Sites on which Iloprost treatment had no effect and sites where Iloprost led to (ii) reduced or (iii) increased phosphorylation; the latter containing putative PKA targets ( fig. 4 ). We focused on sites that showed a particularly strong and/or immediate Iloprost-dependent deviation from the ADP temporal profile as these might comprise critical processes that are reversed upon platelet de-activation, indicating potential candidates for assessing the overall platelet activation status, e.g.
from patients receiving anti-purinergic receptor medication. As expected, primarily sites within PKA consensus motifs were up-regulated upon Iloprost treatment, among those CLDN5 Thr207 , ENSA Ser109 , MYO9B Ser1354 , SLAIN2 Ser391 , UBE20 Ser515 , MRVI1/IRAG 657 , ARPP19 Ser104 , PDE3A Thr311/Ser312 , STXBP5 Ser759 , and CALDAG-GEFI Ser587 . In contrast, ROCK2 Ser1374 , SCARF Ser610/611 , DAPP1 Ser274 , FLNA Ser1976 , SSFA Ser1055 , TC2N Ser83/Tyr84 , TMSB4X Thr34 , CAMK2D Ser315/Ser319 , MYCT Ser114 , MYCT Ser117 , and ASAP1 Ser910 showed a strong down-regulation. This indicates that particularly the following critical events are triggered: (i) cytoskeletal rearrangement is reversed (MYO9B, SLAIN2, ROCK2, FLNA, SSFA2, TMSB4X), (ii) the further release of granules may be altered (ENSA and ARPP19 both interact with SNCA and phosphorylation of ENSA Ser109 seems to disrupt ENSA/SNCA interaction; STXBP5), (iii) Ca 2+ homeostasis/signaling (IRAG, TC2N, CAMK2D) is affected, as well as (iv) cAMP/cGMP levels (PDE3A). Furthermore, Rap1b is inactivated by CALDAG-GEFI and SCARF1-mediated binding of Ac-LDL seems to be affected. Interestingly, for five phosphorylation sites in ENSA, G6B, RASGRP2/CALDAG-GEFI, SHROOM4, and DNM2 we detected inverse regulation upon treatment with Iloprost. ENSA Ser109 is a known PKA site which is dephosphorylated upon ADP stimulation, such as CALDAG-GEFI Ser587 which is a key regulator of integrin activation. 27 G6b is phosphorylated after platelet activation downstream of integrin αIIbβ3 at two Tyr residues (Tyr211, Tyr237). 28 This phosphorylation constitutes the For personal use only. on October 28, 2017. by guest www.bloodjournal.org From inhibitory role of G6b which is conveyed by interaction with the SH2-domains of SHP1 and SHP2. 29 The G6B Ser/Thr phosphorylation sites found here are not associated with any particular function, yet, however are within AGC-kinase consensus motifs.
The role of SHROOM4 Thr590 is not fully understood, but it appears act in the regulation of cell morphology 30 and the consensus motif 586 ERFApTN 591 is rather untypical.
To investigate the occurrence of additional phosphorylation sites that show a reciprocal behavior upon platelet activation/inhibition, we compared the two novel platelet phosphoproteomics data sets presented here with our previous study on sole Iloprost stimulation. 14 Together they comprise 500 differential phosphoproteins, among those 21 showed a potential reciprocal regulation. We therefore sought to validate these findings with an independent approach. Notably, the validation of often unknown phosphorylation sites is extremely challenging, due to either the (complete) lack of specific antibodies. Owing to this severe absence of available tools, we utilized a "targeted" mass spectrometry approach, namely parallel reaction monitoring (PRM) 31, 32 , to validate selected findings from our large-scale discovery iTRAQ study.
iTRAQ quantification based on so-called data dependant acquistion (DDA) is a powerful approach to provide in-depth and relative fold-changes of thousands of peptides across multiple samples and therefore to discover differential (phospho)peptides. However, as a trade-off to the in-depth analysis the obtained foldchanges can be underestimated 33 . In contrast, PRM allows the specific quantification of only a limited number of selected candidates, e.g. identified in discovery experiments, however with considerably higher precision and accuracy, mainly because of reduced interference from background noise. Notably, PRM can be considered as an antibody-free but MS-based Western blot, which the important advantage that it unambiguously and directly links quantitative measurements with confidently identified targets.
Using PRM we quantified a total of 23 phosphorylation sites among 7 different conditions (resting, 10 s ADP, 30 s ADP, 60 s ADP, 30 s ADP + 30 s Iloprost, 30 s ADP + 60 s Iloprost, 30 s Iloprost) and 5 additional donors. This corresponds to a total of 805 Western blots. We compared the temporal profiles from these PRM assays with those from our iTRAQ data and on average found a good correlation ( fig. 6 ).
Nevertheless, some phosphorylation sites show a considerable inter-individual
variation and rather poor correlation of iTRAQ and PRM data, such as STIM1 Ser618 , ASAP1 Ser839 , or SYTL4 Ser217 . Besides the aforementioned technical reasons, another
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From factor that may contribute to incomplete correlation of iTRAQ and PRM data for specific phospho-sites is that these datasets were obtained from separate experiments and different donors. They represent early time points with rapidly changing phosphorylation levels, therefore phosphorylation patterns of individual proteins may differ at specific time points, also reflecting inter-subject variations in the early ADP response. Given the challenge to reproducibly stimulate multiple platelet samples for exactly 10 seconds, the usage of more elaborate means of sample stimulation and preparation may further reduce such variations in the future. 34 Notably, the lower precision of iTRAQ-based quantification leads to ratio compression. Therefore, the smaller scale of iTAQ ratios was adjusted to the PRM measurements to facilitate the visual comparison (i.e. iTRAQ log2-ratios ranged from -1.2 to 2.8). In most cases, the overall phosphorylation changes For personal use only. on October 28, 2017. by guest www.bloodjournal.org From could be confirmed using an alternative quantification method, additional donors and platelet preparations conducted by different co-workers.
Discussion
We characterized temporal phosphorylation changes in human platelets stimulated with ADP and ADP+Iloprost. Our rationale was that temporal profiles may reveal novel phosphorylation events with important functional roles. As we aimed to provide an overall picture of the phosphorylation events caused by these major regulators of platelet aggregation, we have chosen to carry out the study under conditions were the aggregation process is not abolished. Hence, the detected phosphorylation changes will not exclusively comprise initial P2Y1 and P2Y12 mediated events, but also subsequent synergistic effects due to integrin αIIbβ3 outside-in signaling and thromboxane dependent signaling. Although this was not directly studied, we can confidently assert that the early events with ADP (10 s) and
Iloprost (30 s) are most directly linked to P2Y1, P2Y12 and IP receptor stimulation, respectively.
Protein phosphorylation is commonly studied for rather long incubation times and single time points. Thus, reversible events may be overlooked and the detection of early (primary) and late (secondary) events obscured. ADP stimulation induced phosphorylation changes on 302 proteins (ST 3), for 254 already regulated after 10 s.
In accordance with Stalker et al., 4 we grouped regulated proteins into four categories:
(i) initial processes of activation; (ii) aggregation; (iii) degranulation; (iv) ubiquitin ligases (see also supplemental results).
(i) Initial processes of activation
Many proteins of this category were regulated upon ADP stimulation (detailed in supplemental results); among those PLCB3, IRAG/MRVI1, Pleckstrin, SDPR, DGKgamma, PKC delta and theta, AVPR1A, IRS1, DAPP1, TWF2, SH3PXD2A, CALDAG-GEFI, PITPNM2, PIKFYVE, STIM1, 14 GEFs, 27 GAPs (table 2) , AMPD2, ROCK1, ROCK2, and MYLK. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From ↑10 ADP corresponds to up-regulation after 10 s of ADP stimulation. If the phosphorylated site could not be localized to a distinct Ser/Thr/Tyr residue with high confidence (e.g. ARHGAP6) all possibly phosphorylated residues are listed, according to the phosphoRS algorithm.
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Platelet integrins can rapidly, reversibly and flexibly change between active and inactive conformations in not fully-understood ways. 35 Our data may provide insight into the involved mechanisms. We found several proteins that modify the activation of platelet integrin receptors, among those CALDAG-GEFI (RASGRP2), RAP1GAP2, TLN, FERMT3, and PPFIA1.
(iii) Degranulation
Degranulation is an irreversible process. A substantial number of proteins (42) regulated after ADP stimulation belong to the GO-term "vesicle-mediated transport".
Notably, the vesicle associated proteins VAMP5 and VAMP8 were regulated upon ADP stimulation, but not upon Iloprost stimulation. Another class of proteins which was only found regulated upon ADP stimulation was syntaxin proteins (STX7). Notably, STXBP5 is a target of activatory (Ser785: ↑10 ADP ; Ser1131: ↑10 ADP ) and inhibitory, PKA-driven (Ser759: ↑30/30 ADP/Ilo ; Ser782: ↑30/30 ADP/Ilo ) signaling. STXB5 can inhibit membrane fusion between transport vesicles and the plasma membrane and has been demonstrated to play an important role in platelet secretion. STXB5-deficient mice showed defective granule secretion and prolonged bleeding times 36, 37 . STXBP5 Ser1131 is conserved between mouse and man and is within a v-SNARE coiled-coil homology domain, which may suggest a regulatory role in SNARE complex formation. SYTL4
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From (Ser217, Ser221: ↑10 ADP ) enhances platelets dense granule release in concert with RAB8A. Additionally, we found several GAPs and GEFs involved in the degranulation process regulated upon ADP stimulation. These include RAB4B (Ser193: ↑10 ADP ), RAB6A (Ser179/Thr180/Ser184: ↓10 ADP ) and RAB13 (Thr72: ↑10 ADP ). According to Yamamoto et al., RAB4, RAB13 and RUFY1 (Ser618: ↑10 ADP ) are involved in endosomal vesicle regulation 38 and might play a vital role in platelets, too.
(iv) Ubiquitin signaling pathways
As in our previous study, 14 we found several ubiquitin ligases regulated upon ADP stimulation. The ubiquitin/proteasome pathway seems to be involved in platelet activation, 39 however, the exact mechanism is unclear. In total, four E3-ubiquitin ligases (HACE1, HUWE1, MYCBP2, ANKIB1) were differentially phosphorylated. HACE1 (Ser381: ↑10 ADP ) was reported to induce Rac degradation upon ubiquitination. 40 Since Rac is a key player during activation, 34 the phosphorylation of HACE1 could lead to an impaired activity. HUWE1 (Thr2540: ↑30 ADP ) interacts with ADP-ribosylation factor (Arf) in leukocytes. 41 MYCBP2, though, is a regulatory switch for receptor internalization 42 which could be of similar importance in human platelets for internalizing and subsequent degradation of PAR receptors (PAR1 Ser418 ↑10 ADP ; PAR4 Ser381 ↑10 ADP ). A similar effect has been shown in HEK cells where CBL (not found regulated in our data) ubiquitinated PAR2, leading to subsequent degradation. 43 At last, ANKIB1 is a potential E3-ubiquitin ligase (Ser898 ↑10 ADP ) with unknown substrates. UBE2J1 (Ser266 ↓30 ADP ) and UBE2O (Ser399 ↑10 ADP , Ser1243 ↑10 ADP ) are ubiquitin conjugating enzymes. Knock-out mice demonstrated an important role for UBE2O in vesicle transport. 44 Furthermore, the regulation of UBASH3B/TULA-2 (Thr34 ↑10 ADP ) might be interesting, as it binds ubiquitinated proteins 45 and dephosphorylates them. 46 In platelets, SYK is primarily dephosphorylated by UBASH3B/TULA-2, inducing a negative regulation of GPVI signaling. 43, 47 Notably, the regulated phosphorylation site is within the ubiquitin binding domain and thus could potentially modulate binding of ubiquitinated proteins.
Novel central nodes involved in reversible platelet activation
In the blood flow, the activation of platelets not contributing to thrombus formation can be reversed by prostacyclin exposed by the endothelium. We wondered whether we could use temporal phosphoproteomics to study this reversal activation For personal use only. on October 28, 2017. by guest www.bloodjournal.org From and thus quantified changes between (i) unstimulated (control) platelets and platelets stimulated (ii) for 30 s with ADP, (iii) for 30 s with ADP followed by either 30 s or (iv) 60 s with 2 nM Iloprost. We further merged all our temporal platelet phosphorylation data sets (i.e. ADP and ADP+Iloprost time series from this study, and our previous Iloprost time series 14 ) to identify phosphorylation sites showing an inverse response ( fig. 7 ). We hypothesize that these might be central players that governing platelet homeostasis and representing suitable candidates for monitoring platelet activation states, such as e.g. done in the VASP phosphorylation assay. 48 For some of these proteins their central roles in platelet activation/inhibition are well-known: G6B, STIM1, PLCB3, PDE3A, RASGRP2, SYTL4, DAPP1, MRVI1/IRAG and FHOD1. However, for others, their functions in platelets are elusive or only partly understood: e.g. for SHROOM4, MTSS1, GSK3A, ENSA, PIKFYVE, PITPNM2, SCARF1, GAPVD1, MYO9B, UBE2O and UBE2J1. fig. 7) show a de-/phosphorylation at Ser312. On the one hand this phosphorylation could induce a negative feedback loop upon Iloprost-mediated signaling, leading to reduced cAMP levels. On the other hand de-phosphorylation upon ADP-mediated signaling could also induce a negative feedback loop by increasing cAMP levels. Our data confirm recent findings that RASGRP2/CALDAG-GEFI Ser587 is crucial for Rap1B signaling; 27 it is clearly down-regulated by ADP (via P2Y12 and Rap1B on) and up-regulated by Iloprost (Rap1B off). We verified these results by Western blotting (fig. 8 ), however, Ser567 down-regulation is not as apparent as in our MS data. Furthermore, we pinpointed the differential GSK3A phosphorylation site to Ser21 using a phospho-specific antibodies ( fig. 8) , showing a down-regulation by ADP and up-regulation by Iloprost. In conclusion, platelet phosphorylation profiles induced by the two fundamental counterparts ADP and prostacyclin produce a complex but consistent picture. A remarkable number of phosphorylation sites and changes have been observed in platelets for the first time, however the function of many of those is still unknown. This renders this dataset a valuable resource for functional studies on promising candidates. It will be important in the future to understand which of the observed initial and later phosphorylation events are mediated by first triggering the P2Y1 and P2Y12 receptors, and subsequent integrin αIIbβ3 outside-in signaling and thromboxane receptor-mediated pathways.
The identification of reciprocal protein phosphorylation may allow the identification of potential marker proteins representing a specific functional state of platelets. Thus, we present a toolbox of reversible phosphorylation sites that should be characterized more in detail, yet raise hope in developing novel assays to monitor platelet activation states for the clinic. By integrating biochemical and functional data/models and quantitative proteomic data 14, 27, 31 novel pharmacological targets can be identified that might pave the way towards precision medicine 49 .
